1029806-23-2

Upstream product

• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 109558-15-8 2-(4-bromophenyl)-N-(3,4-dimethoxyphenethyl)acetamide 
• 114253-66-6 1-(4-bromo-benzyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline oxalate 
• 606978-01-2 1-(4-Bromo-benzyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 355004-67-0 (4-methoxypyridin-3-yl)boronic acid 

Downstream Products

• 1029806-24-3 6,7-dimethoxy-1-[4-(4-methoxypyridin-3-yl)benzyl]-1,2,3,4-tetrahydroisoquinoline hydrochloride 
• 1030137-86-0 6,7-dimethoxy-1-[4-(4-methoxypyridin-3-yl)benzyl]-2-methyl-1,2,3,4-tetrahydroisoquinoline 
• 1029806-25-4 6,7-dimethoxy-1-[4-(4-methoxypyridin-3-yl)benzyl]-2-methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride 

Relevant academic research and scientific papers

COMPOUNDS FOR THE TREATMENT OF GLIOMA

Disclosed are compounds for the treatment of cancer. Compounds disclosed particularly effective for the selective inhibition of glioma cells.

THERAPEUTIC TETRAHYDROISOQUINOLINE-BASED COMPOSITIONS FOR CANCER THERAPY

Disclosed are therapeutic tetrahydroisoquinoline compositions for the treatment of cancer, these compositions having selectivity for cancer cells while demonstrating few, if any, deleterious side effects on normal cells.